CN105121464B - 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽 - Google Patents

用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽 Download PDF

Info

Publication number
CN105121464B
CN105121464B CN201480005077.6A CN201480005077A CN105121464B CN 105121464 B CN105121464 B CN 105121464B CN 201480005077 A CN201480005077 A CN 201480005077A CN 105121464 B CN105121464 B CN 105121464B
Authority
CN
China
Prior art keywords
fgfr3
sfgfr3
polypeptide
treatment
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480005077.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105121464A (zh
Inventor
埃尔维雷·古兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
French Institute Of Health And Medicine
Universite de Toulouse
Original Assignee
French Institute Of Health And Medicine
Universite Toulouse III Paul Sabatier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by French Institute Of Health And Medicine, Universite Toulouse III Paul Sabatier filed Critical French Institute Of Health And Medicine
Publication of CN105121464A publication Critical patent/CN105121464A/zh
Application granted granted Critical
Publication of CN105121464B publication Critical patent/CN105121464B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201480005077.6A 2013-01-16 2014-01-16 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽 Expired - Fee Related CN105121464B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2013/001480 WO2014111744A1 (en) 2013-01-16 2013-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
WOPCT/IB2013/001480 2013-01-16
PCT/EP2014/050800 WO2014111467A1 (en) 2013-01-16 2014-01-16 A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders

Publications (2)

Publication Number Publication Date
CN105121464A CN105121464A (zh) 2015-12-02
CN105121464B true CN105121464B (zh) 2021-05-07

Family

ID=48289519

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480005077.6A Expired - Fee Related CN105121464B (zh) 2013-01-16 2014-01-16 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽

Country Status (19)

Country Link
US (5) US20150344855A1 (enExample)
EP (2) EP2945967B1 (enExample)
JP (3) JP2016506914A (enExample)
KR (3) KR20160002681A (enExample)
CN (1) CN105121464B (enExample)
AU (2) AU2013373679A1 (enExample)
CA (2) CA2898415A1 (enExample)
DK (1) DK2945967T3 (enExample)
EA (2) EA201591324A1 (enExample)
ES (1) ES2796743T3 (enExample)
HU (1) HUE049556T2 (enExample)
IL (2) IL239810A0 (enExample)
MX (2) MX372787B (enExample)
PE (1) PE20151664A1 (enExample)
PL (1) PL2945967T3 (enExample)
PT (1) PT2945967T (enExample)
SG (2) SG11201505488XA (enExample)
SI (1) SI2945967T1 (enExample)
WO (2) WO2014111744A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
CA2972865A1 (en) 2015-01-07 2016-07-14 Therachon Sas Soluble fgfr3 decoys for treating skeletal growth disorders
KR20170121719A (ko) * 2016-04-25 2017-11-02 장부다 Vr 공간에서 사용자 인터페이스를 제공하는 방법, 디바이스 및 기록매체
WO2018007597A1 (en) 2016-07-07 2018-01-11 Therachon Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
MX2020003114A (es) * 2017-09-20 2020-10-20 Pfizer Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3).
CN108410803B (zh) * 2018-03-28 2019-02-05 湖南源品细胞生物科技有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
WO2022106976A1 (en) 2020-11-18 2022-05-27 Pfizer Inc. Stable pharmaceutical formulations of soluble fgfr3 decoys
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030068313A1 (en) * 2001-09-28 2003-04-10 Kazuwa Nakao Therapeutic agents for achondroplasia
WO2004110487A1 (en) * 2003-06-17 2004-12-23 Prochon Biotech Ltd. Treatment of t cell mediated diseases by inhibition of fgfr3
CN101585866A (zh) * 2009-07-02 2009-11-25 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
CN102219860A (zh) * 2011-05-20 2011-10-19 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308236D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Dna vectors
DE69619526T2 (de) 1995-06-12 2002-10-31 Yeda Research And Development Co., Ltd. Fgf9 als spezifischer ligand für fgfr3
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7029872B2 (en) 2000-06-28 2006-04-18 Glycofi, Inc Methods for producing modified glycoproteins
US7598055B2 (en) 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
CA2432257A1 (en) * 2000-12-18 2002-06-27 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
JP4252746B2 (ja) * 2001-10-05 2009-04-08 一和 中尾 軟骨無形成症治療剤
JP2003104908A (ja) * 2001-09-28 2003-04-09 Ichikazu Nakao 軟骨無形成症治療剤
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
JP4970057B2 (ja) * 2004-02-24 2012-07-04 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
EP1910542B1 (en) * 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
CA2664921A1 (en) 2006-09-28 2008-04-03 Hepacore Ltd. N-terminal fgf variants having increased receptor selectivity and uses thereof
CL2007003411A1 (es) 2006-11-28 2008-07-04 Centelion Proteina fusion que consiste en una region fc de una inmunoglobulina con un fragmento o dominio soluble de un receptor para fgf; polinucleotido que la codifica y vector y celula que lo comprenden; composicion farmaceutica que comprende la proteina fu
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
US8426396B2 (en) 2008-01-08 2013-04-23 Shriners Hospitals For Children Treatment for achondroplasia
WO2010002862A2 (en) 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CA2732449A1 (en) 2008-08-04 2010-02-11 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
TWI381848B (zh) 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
PE20120553A1 (es) 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
US8445445B2 (en) 2009-09-15 2013-05-21 Five Prime Therapeutics, Inc. Method of promoting hair growth using FGFR4 extracellular domains
ES2600631T3 (es) 2009-11-13 2017-02-10 Five Prime Therapeutics, Inc. Uso de proteínas del dominio extracelular de FGFR1 para tratar cánceres caracterizados por mutaciones activadoras dependientes de ligando en FGFR2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
US20120328599A1 (en) 2010-01-14 2012-12-27 Yale University Inhibitors of receptor tyrosine kinases (rtk) and methods of use thereof
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
EP2658979B1 (en) * 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
BR112014009797A2 (pt) 2011-10-24 2020-10-27 Halozyme, Inc. diagnóstico de companhia para terapia de agente anti-hialuronano e métodos de uso do mesmo
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
AU2013295805B2 (en) 2012-07-24 2019-05-02 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
CA2878183A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
AU2013337264B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
CA2972865A1 (en) 2015-01-07 2016-07-14 Therachon Sas Soluble fgfr3 decoys for treating skeletal growth disorders
WO2018007597A1 (en) 2016-07-07 2018-01-11 Therachon Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
MX2020003114A (es) 2017-09-20 2020-10-20 Pfizer Tratamiento de deposicion anormal de grasa visceral utilizando polipeptidos de receptor 3 de factor de crecimiento de fibroblastos soluble (sfgfr3).

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030068313A1 (en) * 2001-09-28 2003-04-10 Kazuwa Nakao Therapeutic agents for achondroplasia
WO2004110487A1 (en) * 2003-06-17 2004-12-23 Prochon Biotech Ltd. Treatment of t cell mediated diseases by inhibition of fgfr3
CN101585866A (zh) * 2009-07-02 2009-11-25 中国人民解放军第三军医大学野战外科研究所 调节fgfr3活性的多肽及其筛选方法和应用
CN102219860A (zh) * 2011-05-20 2011-10-19 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia;Min Jin等;《Human Molecular Genetics》;20120926;第21卷(第26期);第5443-5455页 *
Approches translationnelles chez l’enfant;J.-P. Salles等;《La recherche clinique en pédiatrie》;20090601;第16卷(第6期);第664-666页 *
FGFR3突变与软骨发育不全的研究进展;张明等;《中国优生与遗传杂志》;20101231;第18卷(第5期);摘要 *
fibroblast growth factor receptor 3 isoform 2 precursor [Homo sapiens];van Rhijn，B.W等;《GenBank》;20121209;ACCESSION：NP_075254.1 *
NF449 Is a Novel Inhibitor of Fibroblast Growth Factor Receptor 3 (FGFR3) Signaling Active in Chondrocytes and Multiple Myeloma Cells;Pavel Krejci等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;20100702;第285卷(第27期);第20644-2065页 *

Also Published As

Publication number Publication date
PE20151664A1 (es) 2015-11-28
CA2896978A1 (en) 2014-07-24
KR20150122136A (ko) 2015-10-30
EP2945967B1 (en) 2020-04-15
DK2945967T3 (da) 2020-07-13
MX2015009142A (es) 2015-11-06
IL239996A0 (en) 2015-08-31
WO2014111467A1 (en) 2014-07-24
US20210032608A1 (en) 2021-02-04
MX2019013857A (es) 2020-01-20
IL239810A0 (en) 2015-08-31
KR20210054026A (ko) 2021-05-12
KR102249454B1 (ko) 2021-05-07
SG11201505488XA (en) 2015-08-28
JP2016506912A (ja) 2016-03-07
EP2945967A1 (en) 2015-11-25
US20210032607A1 (en) 2021-02-04
CN105121464A (zh) 2015-12-02
US20150344855A1 (en) 2015-12-03
US20200199545A1 (en) 2020-06-25
JP2019107006A (ja) 2019-07-04
JP6995069B2 (ja) 2022-02-04
US20150353624A1 (en) 2015-12-10
HK1217959A1 (zh) 2017-01-27
US11702642B2 (en) 2023-07-18
WO2014111744A1 (en) 2014-07-24
AU2014206844A1 (en) 2015-07-16
JP2016506914A (ja) 2016-03-07
MX372787B (es) 2020-07-03
PT2945967T (pt) 2020-05-28
HUE049556T2 (hu) 2020-09-28
US11814654B2 (en) 2023-11-14
ES2796743T3 (es) 2020-11-30
SG11201505140XA (en) 2015-07-30
CA2898415A1 (en) 2014-07-24
EP3736285A1 (en) 2020-11-11
AU2013373679A1 (en) 2015-08-13
SI2945967T1 (sl) 2020-10-30
PL2945967T3 (pl) 2020-11-16
US10724014B2 (en) 2020-07-28
EA201591055A1 (ru) 2016-04-29
KR20160002681A (ko) 2016-01-08
EA201591324A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
CN105121464B (zh) 用于预防或治疗骨骼生长迟缓病症的可溶性成纤维细胞生长因子受体3(fgr3)多肽
KR102833432B1 (ko) 조직 석회화의 치료 방법
EP3242888B1 (en) Solube fgfr3 decoys for treating skeletal growth disorders
US20200297799A1 (en) Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides
JP2020015733A (ja) 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
HK40039498A (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
HK1217959B (en) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
RU2794170C2 (ru) ЛЕЧЕНИЕ АНОМАЛЬНОГО ОТЛОЖЕНИЯ ВИСЦЕРАЛЬНОГО ЖИРА С ИСПОЛЬЗОВАНИЕМ РАСТВОРИМЫХ ПОЛИПЕПТИДОВ РЕЦЕПТОРА ФАКТОРА РОСТА ФИБРОБЛАСТОВ 3 (sFGFR3)
HK40050674A (en) Soluble fgfr3 decoys for treating skeletal growth disorders
HK1246313B (en) Soluble fgfr3 decoys for treating skeletal growth disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210507

CF01 Termination of patent right due to non-payment of annual fee